NEWS
Chutes & Ladders—Immunomedics taps Ipsen exec Semerjian as CEO
| FierceBiotech

Semerjian, who comes from being Ipsen’s chief commercial officer and executive vice president and also served a major 16-year stint at Novartis Oncology, will now head up the biotech as it looks to the summer for a potential approval after one of the most tortuous paths in biotech lore. There is a long history here that […]

NeuBase Sets a Course for the Clinic
| GEN Edge News

Pittsburgh developer of next-gen antisense oligonucleotide therapies says data generated from a pharmacokinetic study in non-human primates (NHPs) and in vitro pharmacodynamics studies in patient-derived Huntington’s disease (HD) cell lines supports its decision to advance the development of its lead programs in Huntington’ disease and myotonic dystrophy type 1, and expand its pipeline into other indications . […]

Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More
| Xconomy

The COVID-19 pandemic has stopped enrollment in many clinical trials and postponed the start of others but there is still life in the life sciences sector. The coronavirus research is expected. It’s the other activity that might come as a surprise. Two biotech companies have gone public in the past week; each upsized its offering and […]